Heidelberg Pharma AG Stock
Heidelberg Pharma AG Stock
There is an upward development for Heidelberg Pharma AG compared to yesterday, with an increase of €0.040 (1.320%).
So far the community has only identified positive things for Heidelberg Pharma AG stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Heidelberg Pharma AG in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Heidelberg Pharma AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Heidelberg Pharma AG | 1.320% | -3.226% | -1.316% | 15.385% | 24.481% | -37.370% | -61.440% |
| Vivoryon Therapeutics N.V. | -0.440% | -1.879% | -1.594% | -28.072% | -6.086% | -90.244% | -90.647% |
| Nanorepro AG | -5.590% | -9.416% | -7.616% | 8.560% | -7.309% | -32.609% | -91.389% |
| Vaxart Inc. | - | 0.000% | 52.703% | 14.049% | 101.786% | -19.994% | -89.820% |
Comments
systinvest bought the security Heidelberg Pharma AG in his wikifolio Aktienwertselektion mit System.
Show more
News
EQS-News: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
EQS-News: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
EQS-Adhoc: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
EQS-Adhoc: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
EQS-News: Heidelberg Pharma Received Development Milestone Payment from Partner Takeda
EQS-News: Heidelberg Pharma Received Development Milestone Payment from Partner Takeda